Programmed Cell Death Protein-1 (PD-1) Monoclonal Antibody for EBV-HLH and CAEBV as First-line Therapy

  • End date
    Apr 30, 2023
  • participants needed
  • sponsor
    The First Affiliated Hospital of Soochow University
Updated on 15 September 2021


EBV-HLH and CAEBV are both caused by EBV infection, part of them can rapidly lead to a syndrome of severe, life-threatening hyper-inflammation, with poor prognosis. Currently, the most effective treatment remains unknown. This study is trying to evaluate the efficacy and safety of PD-1 monoclonal antibody as a first-line therapy for EBV-HLH and CAEBV.


Eligible patients who were diagnosed with EBV-HLH or CAEBV, age between 12 and 70 years, were enrolled in this study. All of them need to sign the informed consent first.

PD-1 monoclonal antibody 200mg is infused intravenously once for patients whose age >=18 years, or age <18 years but weight >=40kg. While for patients age <18 years, the dose of PD-1 monoclonal antibody is 3mg/kg. Besides, optimal supportive care is necessary.

Ruxolitinib and/or low-dose glucocorticoid can be used to reduce inflammation.

Cerebrospinal fluid parameters are examined, and methotrexate 15mg combined with dexamethasone will be intrathecal injected without contraindications.

Clinical and laboratory indicators are investigated weekly to evaluate the efficacy and toxicity.

If patients achieve partial response/complete response within 14 days after PD-1 monoclonal antibody, the clinical observations are stopped. If not, the observation period is prolonged to 21 days.

If disease progress at day 21, this study is terminated, and the patient should be transfer to other treatments as soon as quickly.

Condition ebv infection, EPSTEIN BARR VIRUS INFECTION
Treatment PD-1 monoclonal antibody
Clinical Study IdentifierNCT05039580
SponsorThe First Affiliated Hospital of Soochow University
Last Modified on15 September 2021


Yes No Not Sure

Inclusion Criteria

Meet the diagnostic criteria of EBV-HLH or CAEBV
Newly diagnosed patients
Eastern Cooperative Oncology Group score 0-3
Total bilirubin <= 10 times of upper limit of normal (except for those caused by EBV-HLH or CAEBV), and serum creatinine <= 1.5 times of upper limit of normal
Serum HIV antigen or antibody is negative
Hepatitis C virus (HCV) antibody is negative, or HCV antibody is positive, but HCV-RNA is negative
Both HbsAg and HbcAb for Hepatitis B virus (HBV) are negative. If not, the quantification of HBV-DNA needs to be <110e3 IU/ml
The patient or his/her guardian must be able to understand and be willing to participate in this study, and sign the informed consent

Exclusion Criteria

Non EBV-HLH or CAEBV patients
Refractory or relapsed EBV-HLH or CAEBV
Heart function above grade II (NYHA)
Patients suffered from other uncontrollable active infections
Pregnant or lactating women
Patients with mental disorders and cannot cooperate with the requirements of research, treatment and monitoring
Active visceral bleeding
Allergic to PD-1 monoclonal antibody
Patients with known autoimmune diseases
Participate in other clinical research at the same time
The investigator judges that the patient has other reasons not suitable for this study, or participating in the study will bring great risks to the patient
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note